Vertex Pharmaceuticals Incorporated (VRTX)

VRTX · Health Care · United States

Vertex Pharmaceuticals Incorporated (VRTX) is a US company in the Health Care sector. The stock has its largest weight in XUHL (MSCI USA Health Care), at 2.04%. Anyone who holds an ETF containing Vertex Pharmaceuticals Incorporated also has an indirect stake in the company.

Data and Charts: Vertex Pharmaceuticals Incorporated

Key Data for Vertex Pharmaceuticals Incorporated

Data note 1

Vertex Pharmaceuticals Incorporated Stock Price Chart

The Vertex Pharmaceuticals Incorporated chart shows daily closing prices and is set to the current year by default. The stock is up 23.3% year to date and up 33.1% over twelve months. The last recorded close on October 30, 2026, was $558.88, at 100% of the 52-week range.

Price series from our database since Aug 12, 2024, 558 daily values.

Data note 2

Vertex Pharmaceuticals Incorporated Stock Performance

Data note 3

Measured in euros, Vertex Pharmaceuticals Incorporated is up 29.7% year to date and up 37.6% over twelve months. The difference from the dollar figures above comes from the exchange rate alone. Each daily price is converted at the ECB euro reference rate for that day.

Data note 4

Alysly Data Analysis: Vertex Pharmaceuticals Incorporated

What ETF Is Vertex Pharmaceuticals Incorporated In?

Data note 5

Data note 6

The last column shows how much of €1,000 in one of these funds goes to Vertex Pharmaceuticals Incorporated, based on each fund's latest holdings list.

US-listed ETFs holding Vertex Pharmaceuticals Incorporated (weight per latest SEC filing): QQQM 0.61%, QQQ 0.55%, VUG 0.36%, ONEQ 0.30%, IVV 0.20%, SPY 0.20%, VOO 0.20%, VTI 0.17%. These funds are registered in the US; retail investors in the EU usually cannot buy them.

Vertex Pharmaceuticals Incorporated Weight in iShares Core MSCI World (EUNL) Since 2019

In iShares Core MSCI World (EUNL), Vertex Pharmaceuticals Incorporated had a weight of 0.10% on Sep 30, 2019 and 0.15% on Oct 29, 2026. The fund tracks the MSCI World. Its share peaked at 0.18% on Jun 30, 2020. The weight rises and falls with the stock's price performance relative to the other index members. It can also change when the index provider adjusts the index composition.

Data note 7

What's Inside Your ETF Portfolio and the ETF overlap check show how much Vertex Pharmaceuticals Incorporated overlaps with the rest of a portfolio.

Which Tracked Investors Hold Vertex Pharmaceuticals Incorporated?

Vertex Pharmaceuticals Incorporated is not among the largest purchases in the quarter ending Jun 30, 2026. The list is led by GOOGL, DAL and NEBIUS GROUP N.V. The only manager we track that holds Vertex Pharmaceuticals Incorporated reduced its position.

As of Jun 30, 2026. Based on quarterly filings with the US securities regulator, submitted up to 45 days after the reference date. The change counts shares, not price gains.

Data note 8

Stocks With ETF Exposure Similar to Vertex Pharmaceuticals Incorporated

Stocks with ETF exposure similar to Vertex Pharmaceuticals Incorporated

Stock	Shared ETFs	r	1 year	Annualized volatility	Net margin	Revenue growth
Vertex Pharmaceuticals Incorporated	–	–	+33.1%	31.8%	32.9%	+8.9%
Gilead Sciences	26	–	+44.1%	26.8%	28.9%	+2.4%
IDEXX Laboratories	25	–	-12.3%	36.6%	24.6%	+10.4%
Amgen	25	+0.64	+59.6%	27.7%	21.0%	+10.0%
Regeneron Pharmaceuticals	24	–	+41.9%	36.5%	31.4%	+1.0%
DexCom	24	–	+20.7%	40.8%	17.9%	+15.6%
Intuitive Surgical	23	–	-18.5%	34.2%	28.4%	+20.5%
Edwards Lifesciences Corporation	22	–	+10.2%	25.0%	17.7%	+11.5%
HCA Healthcare Inc	22	–	+1.4%	29.0%	9.0%	+7.1%

These stocks reach a portfolio through largely the same funds as Vertex Pharmaceuticals Incorporated. “Shared ETFs” counts the funds that hold both.

Return and volatility are calculated from our daily closing prices in US dollars. Margin and growth come from each company's latest SEC annual filing. Because fiscal years do not end on the same date for every company, the underlying periods are not fully identical.

Data note 9

Fundamental Analysis: Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated Key Financials

Figures come from the SEC annual filing for the latest reported fiscal year (period end Dec 31, 2025).

Data note 10

Technical Analysis: Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated Risk Metrics

Data note 11

The close on Oct 30, 2026, was the highest since our series began on Aug 12, 2024. When the S&P 500 rose or fell 1%, Vertex Pharmaceuticals Incorporated moved 0.45% on average in the same direction (past 252 trading days). The correlation of 0.20, however, shows only a moderate link to the broad market. Accordingly, moves in the S&P 500 explain only a small part of the daily price moves of Vertex Pharmaceuticals Incorporated.

Data note 12

What Vertex Pharmaceuticals Incorporated Correlates With

The strongest co-movers are listed at the top, the strongest inverse movers at the bottom. Low or negative correlations can help spread risk more broadly across a portfolio.

Data note 13

Related Content: Vertex Pharmaceuticals Incorporated

Latest Investment Analysis: Stocks

• 
  Oct 31, 2026 · Mixed

  Weekly Analysis: DAX Sets the Tone for the Week (+2.2%) · October 26–30, 2026

• 
  Oct 24, 2026 · Risk-off

  Weekly Analysis: A Quiet Week, MSCI China -4.3% · October 19–23, 2026

• 
  Oct 17, 2026 · Risk-off

  Weekly Analysis: S&P 500 Information Technology Weighs on the Week (-7.7%) · October 12–16, 2026

View all Investment Analysis